Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(60.0%)

N/A

2(40.0%)

5Total

Phase 2(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07166692Not ApplicableCompleted

Evaluation of a Retrieval Augmented Large Language Model as a Diagnostic Copilot in Rheumatology

Role: collaborator

NCT04397237Unknown

Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe

Role: collaborator

NCT01395251Phase 2Completed

Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis

Role: lead

NCT01289730Phase 2Unknown

Etanercept (Enbrel) in Undifferentiated Spondyloarthritis

Role: collaborator

NCT01289743Phase 2Unknown

Etanercept (Enbrel) in Ankylosing Spondylitis

Role: collaborator

NCT01286545Unknown

European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study

Role: lead

NCT00237419Not ApplicableUnknown

Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis

Role: lead

All 7 trials loaded